(Q36216558)

12 August 2017

1 reference

title

Adjuvant chemotherapy for stage II colorectal cancer: the time is right! (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

Rachel Midgley

1

1 reference

12 August 2017

David J Kerr

series ordinal

2

1 reference

12 August 2017

language of work or name

1 reference

1 July 2005

1 reference

Nature Clinical Practice Oncology

12 August 2017

1 reference

12 August 2017

2

1 reference

12 August 2017

364-369

1 reference

12 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/ncponc0228

12 August 2017

0 references

cites work

Colon cancer in France: evidence for improvement in management and survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Adjuvant therapy of colorectal cancer. Why we still don't know

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Counting alleles reveals a connection between chromosome 18q loss and vascular invasion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0228

7 January 2021

Identifiers

DOI

10.1038/NCPONC0228

1 reference

Dimensions Publication ID

12 August 2017

0 references

1 reference